Infliximab in ulcerative colitis

Abstract

Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.

Keywords:

• infliximab
• ulcerative colitis
• anti-TNF-α antibody
• crohn’s disease

Disclosures

Neither author has any conflicts of interest to disclose.